Pharming Group Surpasses Revenue Estimates, Sets Ambitious FY26 Growth Targets
Pharming Group NV has exceeded top-line revenue expectations for the recent period while providing a robust financial roadmap through 2026. The company’s performance underscores the successful commercialization of its rare disease portfolio, contrasting with broader market volatility.